Biomaterials Used in Injectable Implants (Liquid Embolics) for Percutaneous Filling of Vascular Spaces by Jordan, Olivier et al.
Biomaterials Used in Injectable Implants (Liquid
Embolics) for Percutaneous Filling of Vascular
Spaces
Olivier Jordan,1 Eric Doelker,1 Daniel A. Ru¨fenacht2
1School of Pharmacy, University of Geneva, 30 quai Ernest-Ansermet, 1211 Geneva 4, Switzerland
2Department of Neuroradiology, Geneva University Hospital, 24 rue Micheli-du-Crest, 1211 Geneva 14, Switzerland
Abstract
The biomaterials currently used in injectable implants (li-
quid embolics) for minimally invasive image-guided treat-
ment of vascular lesions undergo, once injected in situ, a
phase transition based on a variety of physicochemical
principles. The mechanisms leading to the formation of a
solid implant include polymerization, precipitation and
cross-linking through ionic or thermal process. The bioma-
terial characteristics have to meet the requirements of a
variety of treatment conditions. The viscosity of the liquid is
adapted to the access instrument, which can range from 0.2
mm to 3 mm in diameter and from a few centimeters up to
200 cm in length. Once such liquid embolics reach the
vascular space, they are designed to become occlusive by
inducing thrombosis or directly blocking the lesion when
hardening of the embolics occurs. The safe delivery of such
implants critically depends on their visibility and their
hardening mechanism. Once delivered, the safety and
effectiveness issues are related to implant functions such as
biocompatibility, biodegradability or biomechanical prop-
erties. We review here the available and the experimental
products with respect to the nature of the polymer, the
mechanism of gel cast formation and the key characteristics
that govern the choice of effective injectable implants.
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Image-guided minimally invasive techniques have become
widely used to treat arteriovenous malformations (AVMs),
aneurysms and tumors. This evolution arises from the pro-
gress in percutaneous lesion access and performance of the
deliverable implants. These implants are designed to em-
bolize the vascular spaces once injected in a liquid form,
either by directly occluding them or by inducing a second-
ary local thrombosis. Besides the use of coils, balloons or
particles, the so-called liquid embolics have met success
partly due to their ability to form a gel cast that completely
fills the vascular defect. One of the key material charac-
teristics influencing the clinical performance of a liquid
embolic is its solidification mechanism. Various physico-
chemical properties may be involved in the in situ formation
of an implant. Most of the embolics currently used in a
clinical setting rely on either polymerization or precipitation
principles. In the former, monomers or prepolymers poly-
merize in the presence of an initiator into a covalently cross-
linked material (Fig. 1A). As for the precipitating embolics,
a solution of preformed polymer in a water-miscible solvent
is injected, and precipitates into a solid cast following ex-
change of the solvent with surrounding physiologic water
(Fig. 1B). Other physicochemical principles may alterna-
tively be used to produce implants in situ. Changes in the
concentration of ionic species (Fig. 1C) or changes in pH
may also induce the required phase transition. Finally,
thermosensitive gels can solidify under temperature change,
e.g., from room to body temperature.
Materials for Liquid Embolization
Liquid embolics with clinical precedents and those under
experimental development are listed in Tables 1 and 2,
respectively.
Polymerizing Formulations
Among the existing polymerizing embolics, cyanoacrylate
(CA) glues that undergo polymerization in presence of
blood were proposed in the 1970s [1]. n-Butyl cyanoacrylate
(NBCA) (Histoacryl, Avacryl and Trufill n-BCA) shows a
good combination of penetration and permanence. TrufillCorrespondence to: O. Jordan; email: olivier.jordan@pharm.unige.ch
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n-BCA was approved by the US Food and Drug Adminis-
tration (FDA) for brain AVMs in 2000. NBCA has been
used to induce complete occlusion in kidneys [2, 3] and its
handling was improved by the addition of Lipiodol [4]. A
high number of clinical interventions have been successfully
performed to date [1, 5–8] However, adhesion to catheters
and vascular walls, very rapid polymerization and the need
to add radiopaque agents that interfere with the polymeri-
zation make precise control of the implant delivery difficult
[9–11]. CA glues also induce a significant acute and chronic
Fig. 1. Principles of injectable implant
setting. Three main classes of implant
formation mechanisms: (A) Polymerization of
a monomer or prepolymer (e.g.
cyanoacrylates), (B) precipitation in contact
with bood of a performed polymer solution in
an organic solvent (e.g. EVAL embolics or
Onyx) and (C) Ionic crosslinking of charged
polymer chains in presence of counter-ion
(e.g.) alginate gels).
Table 1. Liquid embolics having clinical precedents
Material Radiopacifier Target Results claimed
NBCA cyanoacrylate Lipiodol, W Tumors (craniofacial and skull base) Effective for preoperative embolization [83, 84]
NBCA cyanoacrylate Lipiodol, W Cerebral or spinal cord AVMs n-BCA equivalent to PVA particles [8]
EVAL Metrizamide Dog kidney, 3 clinical AVMs Satisfactory occlusion [23]
EVAL (Onyx) Ta Pig rete, patient AVM and tumors 12-month occlusion in pigs, 18 patient tumors,
3 AVMs
[30]
EVAL (Onyx) Ta AVMs Non-adhesive embolics. AVM volume reduction
of 63% (23 cases)
[32]
EVAL (Onyx) Ta Cerebral aneurysm Multicenter Onyx Liquid embolics as an alternative to coil treatment.
Occlusion rate superior to coils
[34]
Cellulose acetate polymer Bi2O3 Cerebral AVMs Safe AVM embolization [39]
Cellulose acetate polymer Bi2O3 Aneurysms 80–100% occlusion (8 cases) [37, 85]
Cellulose acetate polymer
and EVAL in DMSO
Ta Rabbit kidneys and Intramuscular
VX2 carcinoma
Liquid embolics outperformed PVA and Gelfoam [28]
Fibrin glue Iopromide Intracranial meningiomas Safe preoperative embolization (80 cases) [69]
Ethibloc Metrizamide,
Lipiodol
Rat kidney and tumors Improvement of Ethibloc radiopacity [45]
Hydrolyzed PVAc ‘‘Embol-78’’
in 44% ethanol
Iopromide 51 preoperative portal vein and 6 renal
artery embolizations
Safety and effectiveness of the procedures [51, 52]
Ethanol – Renal artery, human Treatment of nephrotic syndrome [86]
Ethanol – Brain AVMs Permanent embolization [41]
Acetic acid – Small hepatocellular carcinoma Acetic acid more efficient than ethanol [63]
PMMA cement BaSO4 Vertebral bodies (vertebroplasty) Pain relief, spine stabilization [16]
PMMA cement BaSO4 Vertebral metastases Pain relief [87]
PVA, poly(vinyl alcohol); EVAL, ethylene vinyl alcohol copolymer; NBCA, n-butyl cyanoacrylate; DMSO, dimethyl sulfoxide; W, tungsten; Ta, tantalum
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inflammatory reaction due to toxic reaction products and the
exothermic polymerization [5, 12]. In the search for non-
adhesive CA, promising but still experimental products have
been proposed such as derivatives with long alkyl chains
[13] or 2-hexyl CA (Neuracryl) [14]. Furthermore, an
alternative CA (Glubran) that solidifies through radical ra-
ther than ionic polymerization has been reported to reduce
adhesion to vascular walls in animal experiments [15].
These new materials may renew the interest in CA glues.
Another type of in situ polymerizing implant is used for
bone reinforcement in the field of vertebroplasty. The
material originally proposed by Deramond et al. [16] in the
mid-1980s is a cement that polymerizes into a poly(methyl
methacrylate) (PMMA) cast. Vertebral body filling provides
immediate bone stabilization and, with that, pain relief. In
some instances, intratumoral injection allows a tumor
reduction, attributed to the heat released during the poly-
merization reaction [17, 18]. In comparison with the above-
mentioned cyanoacrylates, the cements have a much higher
rigidity as indicated by their high compression modulus of 2–
5GPa [19], comparable to or higher than that of cortical bone.
Despite their clinical success, the limited bone-bonding and
bone-conducting ability of the acrylic cements spurred the
search for new materials [20]. Cements containing exclu-
sively a mineral phase, such as calcium phosphate cements,
show osteoconductive properties, although their strength is
generally lower than that of PMMA cements. They set by
means of an acid–base reaction resulting in precipitated
calcium salts. Composite cements including a polymerizable
phase and a mineral phase may combine bone bonding with
an early strength [21, 22] provided by the polymer matrix and
hold promise for applications in vertebroplasty.
Precipitating Formulations
In contrast to polymerizing formulations, precipitating li-
quid embolics solidify not after a given time, but when in
contact with physiologic fluids. This results in a specific
behavior when delivering the implant: the delivery may be
paused temporarily during injection to prevent leakage in a
nontargeted vascular or intratumoral space.
A Japanese team initially reported the use of an ethylene-
co-vinyl alcohol (EVAL, also abbreviated EVOH) solution
for AVMs [23] and aneurysm embolization [24] that has
nonadhesive properties when compared with n-butyl cy-
anoacrylates. The organic solvent used to dissolve the co-
polymer, dimethyl sulfoxide (DMSO), raised concerns of
angiotoxicity. Although initial studies did demonstrate va-
sospasms following DMSO injection, subsequent reports
indicated that this effect could be reduced using injection
rates as low as 0.1 ml/min [25, 26]. In addition, as yet
experimental solvents possessing a better hemocompatibil-
ity and reduced hemodynamic side effects could be an
alternative to DMSO for precipitating embolics [27].
An EVAL solution in DMSO opacified with tantalum
was commercialized by Micro Therapeutics Inc. as Embo-
lyx and then Onyx. The latter was used for the successful
embolization of rabbit kidneys [28], swine rete mirabile [29,
Table 2. Liquid embolics under experimental development
Material Radiopacifier Animal model Results claimed
Ethibloc Metrizamide,
Lipiodol
Rat kidney and tumors Improvement of Ethibloc
radiopacity
[45]
NBCA cyanoacrylate Lipiodol Various dog arteries
and kidney
Improved handling [4]
Non-adhesive
isostearyl-2-cyanoacrylate
Lipiodol Renal artery Improved handling,
polymerization control
[13]
NBCA with radical
polymerization
Lipiodol Swine pharyngeal and
renal arteries
Same occlusion rate as NBCA;
lower toxicity and adhesion to vessels
[15]
Cellulose acetate polymer and
EVAL in DMSO
Ta Rabbit kidneys and intramuscular
VX2 carcinoma
Liquid embolics outperforms PVA
and Gelfoam
[28]
EVAL (Onyx 6% to 1%) Ta Rabbit VX2 carcinoma in liver Polymer concentration controls the distal
progression of the embolization
[72]
EVAL (Embolyx E) Ta Swine rete mirabile Permanent occlusion, mild inflammation [29]
Eudragit and NBCA Ta Rabbit external carotid Feasibility shown [61]
Radiopaque polyurethane Not required Pig liver Effective, radiopaque, degradable material [80]
Radiopaque cellulose Not required Sheep kidney Effective and radiopaque material [81]
Alginate hydrogel Conray and Ta Swine AVMs Effective occlusion + 1-week stability [67]
Thermosensitive polymer
(N-isopropylacrylamide)
Iopamidol Rabbit kidney Feasibility, biocompatibility [70]
PVAc latex Iopamidol Dog and rats renal artery + 1
patient AVM
Complete occlusion [65]
PVAc in 50% ethanol Metrizamide Dog middle cerebral artery No recanalization, enhancement after
estrogen embolization
[47]
Eudragit in 50% ethanol Iopromide Rabbit carotid artery, dog renal
artery and 1 patient AVM
Thrombogenic, nonadhesive material, but
edema and necrosis observed
[60–62]
Ethanol None Rabbit and pig renal artery Long-term occlusion + kidney infarction [88]
Ethanol Metrizamide Dog renal artery Ablation mechanism, influence of injection rate. [43]
Ethanol 10–70% None Rat carotid artery/brain Ethanol concentration <40% preserve media [85]
PVAc, poly(vinyl alcohol acetate); EVAL, ethylene vinyl alcohol copolymer; NBCA, n-butyl cyanoacrylate; DMSO, dimethyl sulfoxide; W, tungsten; Ta,
tantalum
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30], and AVMs [31, 33] and aneurysms in humans. More
recently, a multicenter trial demonstrated the safety and
efficacy of Onyx for the embolization of aneurysms in se-
lected patients [34]. It received a CE mark for peripheral
vascular applications (1999) and brain tumors (2000).
Insufficient radiopacity and tantalum sedimentation have,
however, been mentioned as drawbacks [35]. Another pre-
cipitating embolic, a cellulose acetate polymer dissolved in
DMSO [36] and radiopacified with bismuth trioxide, al-
lowed successful embolization of aneurysms [37] and
AVMs [38, 39]. The team reported mild inflammatory
reactions with no chronic granulomatous reaction. It was
also used for embolization of kidneys [28] and spinal arte-
riovenous fistulae [40]. Additional precipitating embolics
have been proposed, based on polyurethane or poly(acry-
lonitrile). Despite interesting properties, these materials
have not yet proven to be safer and more efficient than the
EVAL or cellulose acetate polymers.
Precipitating Sclerosing Formulations
A particular solvent for the precipitating embolics is etha-
nol. It can be an efficient embolization agent when used
alone [41, 42] that damages the endothelium and activates
the coagulation, producing complete infarction of the target
organ or tumor [43]. However, the risk of injury to adjacent
normal tissues is a concern, as well as cardiopulmonary
collapse; some authors recommend limiting the use of eth-
anol to small organs such as kidneys [1]. Low ethanol
concentrations ( £ 40% vol ethanol in water) may be pre-
ferred in order to limit sclerosis to intimal layers and reduce
damage to surrounding tissues [44].
A variety of precipitating embolics based on ethanolic
solutions have been reported. The commercially available
Ethibloc is an ethanolic (57% vol) emulsion based on zein, a
corn protein, that is used to embolize kidney, tumors [45] and
AVMs. Although efficient, the relatively high viscosity of
Ethibloc may restrict its applications [46]. Poly(vinyl ace-
tate) (PVAc) in 50% ethanol has been used following
estrogen embolization to increase the embolization effect
and reduce the risk of hemorrhage [47–49]. In order to in-
crease PVAc solubility, Park et al. [50] proposed a partially
hydrolyzed PVAc, ‘‘Embol-78’’, soluble in 44% ethanolic
aqueous solutions. Its efficiency was demonstrated in pre-
clinical studies for renal [51] and portal vein embolization
[52]. Another promising and nonadhesive embolic is based
on EVAL dissolved in 42% ethanol aqueous solutions, and
has been used clinically to embolize AVMs [53, 54]. Acrylic
copolymers based on hydroxyethyl methacrylate (HEMA)
and methyl methacrylate (MMA) are known for their bio-
compatibility and hemocompatibility. HEMA-co-MMA
dissolved in only 7% ethanol aqueous solution was thus
tested on rabbit kidneys [55] and experimental aneurysms,
and in humans led to efficient embolization of AVMs [56,
57]. Recently, pure HEMA dissolved in concentrated (90%)
ethanol aqueous solutions led to effective embolization in
pig AVM [58] and aneurysm [59] models. Finally, Eudragit,
an acrylic polymer FDA-cleared for pharmaceuticals and
food packaging, as a 50% aqueous ethanol solution, showed
nonadhesive properties and could embolize dog renal arter-
ies. However, a chronic reaction at 2 months [60, 61],
damage to the vessel walls and brain edema necrosis raise
concerns about its use for AVM embolization [62].
A sclerosing alternative to ethanol has been proposed
based on aqueous acetic acid solutions. Comparative clinical
studies claimed that Percutaneous Acetic acid Injection
(PAI) efficiency was similar to or even superior to ethanol
for primary hepatic carcinoma [63]. PAIs were also reported
to be superior to ethanol for the treatment of renal cysts [64].
Alternative Aqueous Embolics
Besides the use of polymerization and precipitation to form
an implant in situ, alternative principles of phase transition
have been proposed. Although still experimental, the
aqueous embolics that are based on water as a solvent may
be attractive due to the absence of potentially toxic mono-
mers, initiators or solvents. The coagulation of charged latex
particles in the presence of ionic species is an example.
Based on this principle, an aqueous emulsion of charged
poly(vinyl acetate) particles have been assessed for the
embolization of AVMs [65]. Though biocompatibility and
effectiveness have been demonstrated, the aggregation re-
mains difficult to control in a surgical setting. An ionically
cross-linkable hydrogel, purified calcium alginate, demon-
strated efficient renal embolization in an acute rabbit model
[66] and 1-week stability in an AVM model [67]. Draw-
backs of this material are the need for double-lumen cath-
eters, concerns regarding the release of non-cross-linked
potentially toxic macromolecules and the limited long-term
stability of the hydrogel cast. Enzymatic cross-linking may
also be used to produce hydrogels, as illustrated by fibrin
glue, a biological material that mimics the coagulation
cascade. Fibrin glue is a two-component material widely
used and FDA-approved as a hemostatic agent (Tisseel,
Hemaseel). It was shown to be safe and effective for the
preoperative embolization of sinus hemangiomas [68] and
intracranial meningioma [69]. Fibrin injection could reduce
bleeding and induce tumor necrosis in the vascular bed.
Despite its biocompatibility, the use of fibrin for AVM
embolization is hindered by its fast degradation and the need
for double-lumen catheterization. Another experimental
strategy is the use of thermosensitive embolics, able to form
a hydrogel when exposed to body temperature. For instance,
gels based on N-isopropylacrylamide embolized mice kid-
neys [70] and poloxamer was used for temporary occlusion
of dog arteries [71]. These different injectable water-based
embolics have been demonstrated to fill in AVMs, vascular
tumors and aneurysms. Despite their good biocompatibility,
these formulations have not proved superior to EVAL or
cyanoacrylates in terms of ease of use or efficiency for
embolization. Further experimental work is required to
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prevent over-rapid degradation that may hamper the clinical
outcome.
Clinically Relevant Characteristics of
the Injectable Implants
The criteria influencing the choice of an appropriate
injectable implant are discussed below. The characteristics
to be considered can be categorized according to the dif-
ferent clinical application steps, i.e., implant delivery, im-
plant function and implant visibility during follow-up
studies.
Implant Delivery
During implant delivery, low-viscosity preparations are
preferred in order to facilitate the injection through small
needles and microcatheters. The higher the viscosity, the
higher the injection pressure required to deliver through
narrow tubing. In the case of high-pressure injections, there
exists a risk of microcatheter or connection adapter failure,
which may lead to loss of implant material with the po-
tential to produce errant implant delivery embolizing non-
target structures. Warning signs for imminent delivery
failure are build-up of the injection pressure during implant
delivery or changes in the diameter of the tubing when non-
braided tubing is used; finally, catheter rupture may be
suspected when a sudden drop in the injection pressure
occurs indicating leakage.
Once the implant has passed through the delivery system
and reached the tissue, the optimal required characteristics
change and include additional criteria such as setting time,
setting mechanism and side effects (e.g., adhesion, toxicity).
Viscosity
Viscosity remains a criterion, with low viscosity and slow
setting favored for conditions where there is a need for high
implant penetration in small vascular spaces. For a given
material, the viscosity of the liquid controls the distal
propagation of the embolization, as shown in liver tumors
[72]. If distal progression is feared, a combination of high
viscosity and a fast setting time may be preferred. As
additional elements to control implant delivery, techniques
of local or general flow control have been described and
may be used to complement implant characteristics [35, 73].
Setting Mechanisms
As outlined above, one of the fundamentally differences
between polymerizing liquids and precipitating liquids is
their behavior during setting. In polymerizing liquids, set-
ting occurs in a narrow predefined time range and is initi-
ated once the implant encounters the reaction initiator. In
contrast, precipitating embolics start losing their solvents as
soon as they are exposed to a miscible environment, i.e.,
within the body tissue, where they form a skin at the
interface with water. This skin slows down the outward
diffusion of the organic solvent, and therefore slows down
the hardening of the deepest part of the implant. Immedi-
ately after injection, a soft material enclosed in a thin skin is
thus obtained. A practical implication of this specific feature
is that the injection of precipitating embolics, such as
EVAL, may be paused when inadequate filling is noticed,
allowing for progressive precipitation of already injected
materials. This can help to build up a local plug preventing
further inadequate filling and redirecting delayed continu-
ous injections of the liquid embolic flow towards other areas
of the target site.
Setting Time
For a given target, the blood flow conditions at the injection
site influence the choice of the implant material. For
occlusion of high-blood-flow lesions such as AVMs, fast-
setting materials such as cyanoacrylates embolics may be
preferable in order to avoid undue progression of the in-
jected implant. Other methods described consist in reducing
the flow by a wedge catheter, use of a calibrated balloon or
by reducing the systemic blood pressure. When dealing with
lesions that exhibit slow flow conditions, slow-setting
compounds may be preferred to allow for better implant
progression during delivery.
Side Effects: Adhesion
Once the implant has been delivered, implant adhesion to
the delivery system (catheter, needle) may lead to its trap-
ping into the embolization site with potential subsequent
adverse effects; this drawback has been consistently re-
ported for most cyanoacrylate glues. Adhesion to the cath-
eter originates from their strong adhesive properties and
their low viscosity [5]. In order to reduce this adhesion, a
hydrophilic-coated catheter, nonadhesive liquid embolics
such as EVAL or modified cyanoacrylates [15, 74], or a
combination of a low-adhesion-risk delivery system and
implant, should be used.
Side Effects: Toxicity
The local adverse effects of precipitating agents (e.g.,
vasospasm) are related to the presence of the organic sol-
vent, and may be circumvented, or at least reduced, by
injecting at a slow maximum rate [25], as outlined above. In
contrast, polymerizing embolics may not induce vasospasms
but may present side effects related to the release of toxic
chemicals during polymerization.
Implant Function
Specific implant functions of interest for current minimally
invasive procedures include biocompatibility, biodegrad-
ability, biomechanical properties and bioactivity.
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Biocompatibility
The biocompatibility may be defined by the nature and
degree of the local, chronic tissue reaction around the
polymeric implant. Whether a strong, mild or no tissue
reaction is required for an appropriate implant function
depends on the specific application and may be controver-
sial. For instance, a strong tissue reaction inducing angio-
genesis may not be desirable in AVMs since it may support
AVM recurrence in the long term. In contrast, for aneurysm
embolization, a controlled tissue reaction could promote
scar tissue formation [75] and facilitate the reconstruction of
the parent artery.
For liquid embolics, implant biocompatibility is related
to the nature of the polymer and the polymer phase change
from liquid to solid. Indeed, polymerizing liquids carry a
risk of chronic inflammatory reaction [5, 12] partly due to
cross-linking agents, initiators and residual monomers or
reaction byproducts. Less inflammation risks exist, in con-
trast, with precipitating nonbiodegradable embolics that
contain none of these elements. Ethibloc, a precipitating
embolic, is an exception, since its protein nature combined
with the alcoholic solvent of the implant mixture typically
induces an inflammatory reaction. Aqueous liquid embolics,
such as fibrin glue or other injectable hydrogels, are likely
advantageous due to their intrinsic potential of being bio-
compatible as a result of their high water content. Hence, if
good biocompatibility is the primary required characteristic,
further development of biostable aqueous embolics may be
of interest.
Biodegradability
The durability of the occlusion is a further factor of relevance
to the choice of an implant material. Biodegradable poly-
meric implants may be suitable for presurgical obliteration of
highly vascularized lesions [68, 69]. Resorbable implants,
such as fibrin glue, are degraded over time and, if applied in,
for example, AVMs, vessel recanalization can be observed.
For AVM treatment, long-lasting effect may be obtained
with nondegradable polymers such as EVAL or cyanoacry-
lates, if material deposition occurs in the arteriovenous shunt
area. With AVMs often exhibiting biologically active reac-
tions that may be independent of the type of implant, the
choice of embolic material may not be the only key to suc-
cess in treating AVMs. Biodegradable implants appear
attractive as a concept if they are replaced in time by bio-
logical tissue, such as might be the case when the implant
would lead to lasting tissue repair in the area of an aneurysm
neck before disappearing. However, the downside lies in the
need to establish good biocompatibility and appropriate tis-
sue remodeling for such materials over the degradation time.
Bioactivity
Some implants may also provide biological activity, in
contrast to the conventional above-mentioned implants that
are biologically mostly inert. Biological activity can be
obtained through the release of a drug, as for instance in
growth-factor-releasing implants [76–78]. Such implants are
designed to support the tissue repair necessary for arterial
wall reconstruction by stimulating the cellular elements that
form a neointima in the aneurysm neck area. The implant
material may also have bioactive properties per se, such as
for the mineral phase in osteoconductive cements. In both
cases, an acceleration of the wound healing process is tar-
geted that, in turn, may improve the integration of the im-
plant into the tissue. Although limited clinical evidence on
their efficacy is available, recent advances in biomaterials
and animal testing of bioactive implants hold promise for
minimally invasive treatment.
Biomechanics
The mechanical properties of the implant should ideally
match those of the target tissue in order to reduce the rel-
ative stress and eventual motion at the implant/tissue
interface that occurs when the tissue is submitted to an
external stress. For instance in the field of vertebroplasty,
the high stiffness provided by PMMA implants leads to
immediate pain relief due to mechanical stabilization.
PMMA cements that exhibit a stiffness superior to normal
bone lead to stiffer than normal vertebral bodies, a condition
that may be considered as a factor facilitating the fractures
in adjacent untreated vertebral segments that are currently
increasingly observed with the use of PMMA in the treat-
ment of osteoporotic vertebral fractures. An adaptation of
the implant to match normal biomechanical values may
potentially reduce this fracture risk. In contrast, preoperative
embolization requires the formation of an elastic cast to
facilitate subsequent surgical removal of the lesion, which is
better achieved with EVAL, celluloses and hydrogels than
with certain cyanoacrylates.
Implant Visibility
For safe delivery, good visibility of the implant under
fluoroscopy is critical. During follow-up studies, visibility
of the implant is also a key factor, although the use of MRI
or CT may require less radiopacity and MR compatibility.
Further, it may be of interest to allow for optimal contrast of
the implant with adjacent structures without production of
imaging artifacts by the implant. In consequence, one has to
negotiate a radiopacity threshold with acceptable minimal
density for fluoroscopy and acceptable density for CT or
MRI. If very high density materials are used, such as the
platinum coils used for cerebral aneurysm filling, CT be-
comes difficult but MR angiography can make up for this
disadvantage—a concept that seems to have been well ac-
cepted within the medical community using this type of
implant. Another disadvantage to consider with the delivery
of very dense implants is the fact that visual control of
additional implants may be hindered by the presence of the
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already present implant. This problem is sometimes
encountered with homogeneously radiopaque implants used
in vertebroplasty procedures or AVM embolizations.
Most of the above-mentioned injectable implants are
made radiopaque by the admixing of contrast agents, either
in a solid form such as powders of tantalum, tungsten or
barium sulfate, or in a liquid form such as Lipiodol or
Ethiodol. Continuing progress in the formulation of radi-
opacifiers has allowed for improvement of the radiopacity
(e.g., Cortoss cements as compared with earlier PMMA
cements). Although the addition of a radiopacifier has
proven to be efficient, its entrapment or its homogeneous
mixing is not always ensured, so that phase separation,
sedimentation or leaching of the radiopacifier may interfere
with the clinical follow-up interpretation [79]. Leaching of
radiopacifiers may potentially also lead to toxic effects.
Polymers with bound radiopaque moieties have been pro-
posed to circumvent the above-outlined problems. For this
purpose, degradable radiopaque polyurethane [80], cellu-
lose-based [81] or vinyl-based radiopaque polymers [82]
have been proposed. Although still experimental, such
intrinsically radiopaque polymers could provide an attrac-
tive alternative to the use of radiopaque agents.
Conclusion
Liquid polymeric formulations that may form an implant
in situ are nowadays used for an increasing number of
indications, thanks to the development of new materials,
improved delivery techniques and a continuous drive to
develop minimally invasive techniques in the interests of
patient care. In a tailored approach, the formulation of the
injectable implant should be selected to fulfill the safety and
efficiency criteria related to implant delivery, implant
function and implant follow-up studies. A key implant
characteristic that governs this choice is the nature of the
physicochemical principle used to produce in situ a solid or
gel-like implant. Key material features are the material
viscosity and setting, the radiopacity, the implant biome-
chanics, the biocompatibility and the biodegradability. Fu-
ture developments towards application-tailored implants
may open the way to clinically useful techniques in the field
of minimally invasive image guided treatment.
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